Activation of the STAT5 signaling pathway up-regulates antiapoptotic protein Bcl2 and drives proliferation of autoreactive conventional CD4 T cells (T cons ). In systemic lupus erythematosus (SLE), an increased T cell Bcl2 content and perturbed homeostasis of CD45RA
FOXP3
hi activated regulatory T cells (aT regs )
were described. We assessed T con /T reg subsets and phosphorylation of STAT5 (pSTAT5) in blood T cells from patients with SLE by using conventional and imaging flow cytometry. Forty-one patients with SLE, 33 healthy controls, and 29 patients with rheumatoid arthritis were included. Long-term monitoring was performed in 39 patients with SLE, which were followed longitudinally for up to 1000 d. Significantly increased Bcl2 protein content in T cells from patients with SLE was associated with IL-7-dependent STAT5 activation, expressed as increased basal levels and nuclear localization of pSTAT5. pSTAT5 levels were significantly increased in the FOXP3 low-expressing CD4 + T cell subsets but not in the aT reg subset, which was significantly decreased in patients with SLE. In contrast to aT reg , SLE T con displayed significantly increased pSTAT5 and Bcl2 levels. Moreover, the percentage of T con -expressing proliferation marker Ki-67 was significantly increased in patients with SLE and was positively correlated with CD4 T cell pSTAT5 levels. Finally, a subgroup of patients characterized by an increased T con -pSTAT5/aT reg -pSTAT5 ratio experienced a more aggressive-relapsing disease course and displayed higher time-adjusted cumulative CD4 T cell pSTAT5 levels during follow-up, which were positively Introduction SLE is a prototype, systemic autoimmune disease characterized by T cell-dependent autoantibodies to nuclear components and immune-mediated injury to essentially any tissue [1] . The pathogenic CD4 T cells have a central role in SLE by providing help to autoantibody-producing B cells and in the inappropriate expression of several cytokines [2, 3] . T cells with a tuned-up survival state, as indicated by a high Bcl2 content, which responded even more strongly to antiapoptotic, homeostatic cytokine signals, were described in patients with SLE [4, 5] . The homeostatic cytokines, such as IL-7, are involved in the survival and homeostatic proliferation of T cells, including autoreactive clones [6] . An inverse relationship between circulating IL-7 levels and CD4 T cell counts was consistently found in various clinical settings [7, 8] , in line with the unique role that IL-7 has in maintaining T cell homeostasis [9] . Homeostatic cytokines bind to receptors that use the common g-chain to signal through JAK3, JAK1, and mainly STAT5 proteins, which are activated by phosphorylation on tyrosine residues. Upon activation, STAT proteins translocate to the nucleus and control numerous gene programs critical for T cell function [10] . It is well known that STAT5 signaling governs CD4 T cell homeostasis [11] and that Bcl2 induction occurs by a mechanism that depends on STAT5 [12] . Priming with the homeostatic cytokines was recently shown to amplify ERK phosphorylation after TCR stimulation, and such TCR sensitization also enabled T cell responses to self-antigens [13] . Abnormal homeostatic cytokine STAT5 signal transduction may be present in SLE T cells to allow survival and expansion of pathogenic autoreactive clones. Autoimmune manifestations in SLE could be driven by such an aberrant signaling, if it persists in pathogenic T cell subsets over time.
The STAT signaling alterations should also be identified in potential disease-ameliorating T regs , which were first shown to actively suppress effector T cells [14] . T regs characterized by FOXP3 expression serve an essential role in maintaining peripheral immune tolerance [15] . The absence of T regs in mouse models leads to systemic autoimmunity with characteristics similar to SLE, including the development of glomerulonephritis and DNA-specific autoantibodies [16] . Numerous CD4 + FOXP3 + T cell abnormalities were described in patients with SLE, such as increased frequency of CD25 2 cells [17] and decreased frequency of the suppressive CD45RA
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hi aT reg subset [18] , suggesting a contribution of a perturbed T reg homeostasis to the disease development. Recent studies have also demonstrated that T regs are subject to distinct homeostatic controls from T cons [19, 20] . However, little is known of the nature of STAT5 signaling dysfunctions in CD4 T cell subsets and their role in perturbed T reg /T con homeostasis and disease progression in patients with SLE. The aim of our study was to investigate whether STAT5 signaling is altered in T cells in the blood of patients with SLE and whether the STAT5 signaling imbalances are related to changes in circulating CD4 T cell subsets and to the disease course during long-term follow-up. By using phospho-specific flow cytometry, our analysis was designed to monitor STAT5 phosphorylation in CD4 + FOXP3 + T cells and compare STAT5 activation directly in T con and subsets of CD4 + FOXP3 + T cells in each patient.
MATERIALS AND METHODS
Study population
Forty-one consecutive patients with SLE, meeting at least 4 ACR SLE criteria [21, 22] , were enrolled into the single-center, prospective cohort study. Thirtynine of 41 patients, who had no moderate or severe disease activity at enrollment (no BILAG score A or B in any system), were followed up to 1000 d. Two patients with SLE did not fulfill inclusion criteria and were excluded from the follow-up analysis. Demographic, clinical, and laboratory data at the time of follow-up study entry are presented in Table 1 . Disease activity was assessed by serial BILAG-2004 and SLEDAI-2000 disease-scoring systems [23, 24] . Treatment data in the cohort of patients with SLE are presented in Table 2 .
During the follow-up, an episode was defined as a discrete disease flare if it met all 3 of the following prospectively defined criteria: 1) new BILAG score A or B in any system, 2) clinical impression of active disease by the reviewing physician, and 3) an increase in immunosuppressive therapy as a result. To differentiate among disease flares, clear improvement in disease activity was required in the form of an improvement in flare-related symptoms together with a reduction in BILAG score and a reduction in immunosuppressive therapy before a further flare could be defined [25] . Disease severity in patients with SLE was assessed with a time-adjusted, cumulative, disease-activity score (adjusted mean SLEDAI) [26, 27] , which was evaluated by 1) calculating the area under the curve between each of the 2 visits, that is, the length of time between the 2 visits, multiplied by the average of the 2 SLEDAI values; 2) adding all calculated areas; and 3) dividing the result by the total length of time. The control groups comprised 33 healthy blood donors and 29 patients with RA (3 men and 26 women; mean age, 58.6 y; mean disease duration, 11.2 y). At the time of blood sample collection, 18 patients with RA were being treated with methotrexate, 6 with an anti-TNF-a biologic drug, 6 with leflunomide, 2 with an anti-IL-6 biologic drug, and 1 with rituximab. Mean disease activity score 28 at the time of blood sample collection was 2.84. All individuals gave informed consent to participate, and the study was approved by the Ethics Committee of the University Medical Centre Maribor and the Slovenian National Medical Ethics Committee.
STAT5 signaling analysis and flow cytometry immunophenotyping
Flow cytometry analysis of basal-and cytokine-induced STAT5 phosphorylation was conducted in EDTA-anticoagulated whole blood by BD Phosflow technology (BD Biosciences, San Jose, CA, USA), according to the manufacturer's instructions. Samples were treated with different concentrations (1-10,000 pg/ml) of recombinant human IL-7 (Thermo Fisher Scientific, Waltham, MA, USA), 100 ng/ml IL-2 (PeproTech, Rocky Hill, NJ, USA), or 1000 ng/ml filgrastim (NEUPOGEN; Amgen Europe BV, Breda, The Netherlands) for 15 min at 37°C or left untreated. Phosphorylation in whole blood samples was stopped by fixation using BD Phosflow Lyse/Fix Buffer (BD Biosciences), and cells were permeabilized with BD Perm Buffer III (BD Biosciences). In selected experiments, whole blood samples were incubated with neutralizing Abs anti-IL-2 (2 mg/ml; clone MQ1-17H12; BD Biosciences) and anti-IL-7 (1 mg/ml; clone BVD10-40F6; BD Biosciences) for 30 min at 37°C before fixation. Cells were stained with anti-CD45-PerCP or APC-Cy7, anti-CD3-FITC or PerCP, and Abs recognizing specific phosphorylated STAT5 tyrosine: pSTAT5 (Y694)-Alexa647 or PE (all BD Biosciences). For multiparametric immunophenotyping experiments, cells were simultaneously stained with anti-Bcl2-PE or anti-Ki-67-PE and Abs specific for T cell subsets: anti-CD4-PECy7 or APC; anti-CD127-APC, anti-CD45RA FITC, or APC; anti-CD25-PE or APC; and anti-FOXP3-Alexa 488 or PE (all BD Biosciences). For immunophenotyping experiments involving T reg subsets defined by CD45RA and FOXP3 expression, Transcription Factor Buffer set (BD Pharmingen, San Diego, CA, USA) was also used according to the manufacturer's instructions. Cells were analyzed on an LSR II Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using FACSDiva software (Becton Dickinson) and FlowJo (TreeStar, Ashland, OR, USA). MFI of the pSTAT5-specific signal was measured. Time-adjusted cumulative CD4 T cell pSTAT5 levels (adjusted mean pSTAT5 MFI) during follow-up were evaluated by 1) calculating the area under the curve between each of the 2 visits, that is, the length of time between the 2 visits, multiplied by the average of the 2 pSTAT5 MFI values; 2) adding all calculated areas; and 3) dividing the result by the total length of time. In addition, to account for interassay variability in samples obtained at various times, the ratio between pSTAT5 MFI values in FOXP3 2 T con and
hi aT reg subsets was calculated. The gate for CD25 + and
Ki-67 + cells was set according to a "flourescence-minus-1 plus isotype" control in which the same Abs were used for staining as in the full stain, except for the anti-CD25 and anti-Ki-67 Ab, respectively, which were substituted with an isotype control Ab labeled with the same fluorochrome.
Assessment of T cell receptor signaling ex vivo
To assess TCR signaling, 200 ml of whole blood was incubated with soluble anti-CD3 (clone UCHT1; BD Biosciences), kept on ice for 15 min, and washed with ice-cold PBS. After centrifugation, supernatants were removed, and goat anti-mouse Ig (polyclonal; BD Biosciences), for CD3 cross-linking, was added. After incubation on ice for 15 min, tubes were transferred to a 37°C water bath. After induction of phosphorylation for 5 min, cells were prepared as 
Analysis of cytoplasmic and nuclear pSTAT5
Whole blood samples were stained for CD3, Bcl2, and phosphotyrosine-STAT5, as described above, and counterstained with 20 ng/ml 7-AAD (BD Biosciences). Image files of cells were collected for each sample using the ImageStreamX imaging flow cytometer (Amnis, Seattle, WA, USA) and were analyzed using IDEAS software (Amnis), as previously described [28] . Infocus, single cells were identified by gating on 7-AAD + events with high nuclear aspect ratios (minor to major axis ratio, a measure of circularity) and high nuclear contrast (as measured by the Gradient Max feature). Among lymphocytes (low SSC/low area of cells), Bcl2 high expressing and CD3 + T cells and CD3 2 cells were gated. Granulocytes with high SSC were also gated on an SSC vs. area dot plot. Nuclear localization of phosphotyrosine-STAT5 within those cells was measured using the similarity score, which quantifies the correlation of pixel values of the nuclear and phosphotyrosine-STAT5 images on a per-cell basis [29] . If the transcription factor is nuclear, the 2 images will be similar and have large positive values. If it is cytoplasmic, the 2 images will not be similar and will have large negative values. Events with positive values .1 had visually apparent nuclear distributions of the transcription factor and were gated to quantify the percentage of cells with nuclear-localized phosphotyrosine-STAT5 within the CD3 + T cells, CD3 2 lymphocyte population, and granulocytes.
ScatterSlice analysis
Cells in EDTA anticoagulated whole blood samples were stained with anti-CD127-APC Abs, than, prepared as described above for analysis of T cell STAT5 signaling and costained with anti-CD3-FITC, anti-CD4-PECy7, and anti-pSTAT5-PE (all BD Biosciences). The purpose of this experiment was to quantify the effects of CD127 (IL-7Ra) on pSTAT5 expression. Initial analysis of flow cytometry data was performed with FlowJo software (TreeStar). Data corresponding to CD3 + T lymphocytes were gated/identified and exported as text files for analysis by processing with the R program ScatterSlice (http:// www.scatterslice.org./). Details of the algorithm have been previously described [30] . Text files are imported into R, and then, divided into userspecified bins. Within each bin, geometric mean fluorescence intensity of the response channel (pSTAT5 in our studies) was calculated for display and further analysis.
Cytokine determinations
Protein levels of IFN-a, IFN-g, IL-7, IL-17F, and IL-17A in serum were measured by cytometric bead array, according to the manufacturer's instructions (BD Biosciences). P value refers to the comparison of group 1 (T con v-pSTAT5:aT reg -pSTAT5 ratio . 1.87) vs. group 2 (T con v-pSTAT5:aT reg -pSTAT5 ratio # 1.87); adjusted P, Bonferroni-adjusted P value; ANA, antinuclear Ab; antidsDNA, anti-double-stranded DNA Abs; aPL + , antiphospholipid Ab positive; CD4%, percentage of CD4 + T cells among lymphocytes; CRP, C-reactive protein; current therapy t 0 , any therapy being taken at time of enrollment; ENA, extractable nuclear antigen; ESR, erythrocyte sedimentation rate; F, female; low C3/4, hypocomplementemia at any time point during follow-up; M, male; NA, not applicable; No. ACR criteria, mean number of ACR classification criteria met; NS, P . 0.05; prednisolone dose t 0 , (equivalent) prednisolone dose being given at time of enrollment bleed; preexisting disease, diagnosis of SLE made before enrollment; renal involvement, biopsy-proven renal SLE involvement; serum Cr, serum creatinine; SLEDAI t 0 , SLEDAI-2000 disease activity index at time of enrollment; t 0 , at time zero enrollment.
a Mean (SEM) or the number of patients/entire group.
Cell preparation, culture, and in vitro IL-7 CD4 T cell stimulation PBMC was separated from peripheral blood by density-gradient centrifugation with Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA). Purified CD4 T cell population was prepared from PBMCs, using negative selection by magnetic cell sorting (BD Imag Human CD4 T Lymphocytes Enrichment Set-DM; BD Biosciences). Cells were cultured in complete RPMI (RPMI 1640 plus L-glutamine, penicillin, streptomycin; Thermo Fisher Scientific) with 10% FCS (Thermo Fisher Scientific). Purified CD4 T cells were cultured for 3 d in the presence or absence of 0.1 ng/ml recombinant human IL-7 (Thermo Fisher Scientific). For flow cytometric analysis of purified CD4 T cells, preparation of the cells was the same as that described above for whole blood, except for cell fixation of cells, BD Cytofix Fixation Buffer (BD Biosciences) was used.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla, CA, USA). A Mann-Whitney test was used for the between-group comparisons, whereas, for the withingroup comparisons, the Wilcoxon matched-pairs signed-rank test was used. A Spearman correlation coefficient was calculated to investigate possible associations between variables. P , 0.05 was considered significant. Follow-up analysis of disease activity was performed using the Kaplan-Meier survival method with a log-rank test of significance between groups. Comparisons of outcome and associated clinical variables between subgroups were analyzed using the nonparametric Mann-Whitney test or the x 2 test as appropriate. The Bonferroni correction for multiple testing was applied to correct for multiple testing where appropriate.
Online supplemental material
The supplemental data provided in this study include data on pSTAT5 in granulocytes from patients with SLE and HCs (Supplemental Fig. 1 ). Supplemental No. of patients/Whole group; P value refers to the comparison of group 1 (T con v-pSTAT5:aT reg -pSTAT5 ratio . 1.87) vs. group 2 (T con v-pSTAT5:aT reg -pSTAT5 ratio # 1.87); adjusted P, Bonferroni adjusted P value; current therapy, therapy being given at time of enrollment; follow-up therapy, therapy given at any time point during subsequent follow-up; induction therapy, therapy given before enrollment to control previous disease flares; NS, P . 0.05; prior therapy, therapy administered before enrollment; t 0 , at time zero enrollment. 
RESULTS
Increased levels of Bcl2 protein and STAT5 phosphorylation in blood T cells from patients with SLE
Levels of Bcl2 protein were investigated by flow cytometry in blood T cells from patients with SLE and healthy donors. MFI of Bcl2 protein expression was significantly increased in CD3 + T cells from patients with SLE (Fig. 1A) .
To examine the role of homeostatic cytokines, we investigated basal pSTAT5 in whole blood leukocytes from patients with SLE ex vivo. High levels of basal pSTAT5 were seen in SLE CD3 + T cells as well in the granulocytes. However, incubation with neutralizing anti-IL-7 Abs decreased high basal levels of pSTAT5 in T cells, but not in granulocytes from patients with SLE (Fig.  1B) . In addition, basal pSTAT5 levels in granulocytes from patients with SLE were not significantly different than those of HCs (Supplemental Fig. 1A ).
Multispectral imaging cytometry was used to analyze intracellular localization of pSTAT5 in whole blood leukocytes from patients with SLE ex vivo ( Fig. 1C and D) . Predominant nuclear localization of pSTAT5 was seen in CD3 + T cells but not in CD3 2 lymphocytes or granulocytes ( Fig. 1C and D) . The percentage of CD3 + T cells displaying nuclear pSTAT5 was significantly higher compared with granulocytes (Fig. 1D) .
In contrast, when whole blood samples from healthy donors were stimulated with filgrastim-recombinant methionyl human granulocyte CSF-significantly increased pSTAT5 MFI levels, and nuclear localization of pSTAT5 were seen in granulocytes but not in CD3 + T lymphocytes (Supplemental Fig. 1B-D) .
Imaging flow cytometry demonstrated that, in contrast to predominantly nonnuclear expression of Bcl2, pSTAT5 was localized to the nucleus in the Bcl2 high expressing T cells from patients with SLE (Supplemental Fig. 2) .
A significant positive correlation between Bcl2 protein content in SLE T cells and pSTAT5 levels, as measured by MFI, was found (Fig. 1E) . Therefore, increased expression of the Bcl2 protein, which is dependent on STAT5 function [12] , was associated with pSTAT5 levels and nuclear localization of pSTAT5 in T cells from patients with SLE.
IL-7-dependent pSTAT5 in CD4 T cells
Levels of pSTAT5 were compared among CD3 + T cells from patients with SLE, healthy donors, and DCs (patients with RA). CD3 + T cell pSTAT5 MFI was significantly increased in patients with SLE compared with both HCs and patients with RA ( Fig. 2A and B) . The highest pSTAT5 levels were found in the CD4 + subset of T cells from patients with SLE (Fig. 2C ).
When patients with SLE were compared with HCs, pSTAT5 levels were significantly increased in CD4 + , but not CD4 2 , subsets of T cells and CD3 2 non-T lymphocytes (Fig. 2D) .
Assessment of cytokine concentrations in the serum of patients with SLE revealed a significant negative correlation between IL-7 levels and their CD4 T cell counts (Fig. 2E) .
Serum IL-7 levels were significantly increased in patients with SLE compared with those of HCs (Fig. 2F) . However, their CD4 T cell counts were not significantly lower than those of HCs (Fig.  2G ). There was no significant correlation between IL-7 levels and pSTAT5 MFI in CD4 T cells from patients with SLE (Spearman correlation coefficient r s = 0.11, P = 0.54).
As all common g-chain cytokines induce pSTAT5 [10, 11] , we investigated whether endogenous IL-2 or IL-7 was responsible for high pSTAT5 in T cells from patients with SLE. Although neutralizing anti-IL-2 Abs did not decrease STAT5 phosphorylation in CD4 T cells in whole blood, incubation with anti-IL-7 Abs decreased high basal pSTAT5 in SLE T cells (Fig. 2H and I) .
The effect of IL-7 on T cell STAT5 signaling is contingent upon expression of IL-7Ra (CD127), forming its high-affinity receptor [10, 11] . Consistent with that, higher pSTAT5 was seen in the CD127 high-expressing population of CD4 T cells from patients with SLE (Supplemental Fig. 3 ).
Because priming with IL-7 was recently shown to amplify p-ERK after TCR stimulation [13] , we also assessed TCR signaling (after CD3 cross-linking) immediately ex vivo-in whole blood CD4 T cells from patients with SLE. In the population of SLE CD4 T cells, characterized by high pSTAT5 levels, p-ERK responses were significantly greater than those in the pSTAT5 low-expressing population of CD4 T cells (Supplemental Fig. 4 ).
FOXP3
+ CD4 + T cell subsets (Fig. 3A) .
pSTAT5 levels were significantly increased in rT reg and non-T reg , but not in aT reg , subsets from patients with SLE compared with HCs. In addition, pSTAT5 levels in SLE aT reg were significantly lower than those in rT reg and non-T reg subsets (Fig. 3B) . This was consistent with the significantly lower IL-7Ra (CD127) expression on aT reg than on rT reg and non-T reg from patients with SLE (Fig. 3C) . Because the T reg suppressive function is linked to both low expression of CD127 and high surface expression levels of IL-2Ra (CD25) [31, 32] , CD25 MFI was also compared among the subsets of FOXP3 + cells from patients with SLE. The highest levels of CD25 expression were found on aT reg (Fig. 3D) , which have previously been shown to be the most suppressive-effector T reg subset among FOXP3 + cells [18, 33] .
Because increased frequency of CD25 2 FOXP3 + cells was reported among CD4 T cells from patients with SLE [17] , pSTAT5 levels were compared between CD25 + and CD25 2 subsets of FOXP3 + CD4 + T cells (Supplemental Fig. 5A ). pSTAT5 levels were not significantly different in CD25 2 FOXP3 + than they were in the CD25 + FOXP3 + subset of CD4 T cells from patients with SLE and were significantly increased in both subsets compared with HCs. (Supplemental Fig. 5B) . Therefore, because IL-2-induced STAT5 signaling is dependent on IL-2Ra (CD25) expression, increased STAT5 activation, even in FOXP3 + subsets from patients with SLE, appeared not to be driven by IL-2.
Both FOXP3 + subsets were significantly increased among CD4 T cells from the patients with SLE compared with HCs (Supplemental Fig. 5C ).
Analysis of the expression of CD39, which conveys T regmediated suppression through extracellular ATP hydrolysis and, therefore, serves as a surrogate marker for its suppressive capacity [34, 35] , did not show significant differences between CD25 + and CD25 2 subsets of FOXP3 + cells from patients with SLE (Supplemental Fig. 5D ). However, a significantly higher percentage of CD39 + cells was found in the FOXP3 high-expressing aT reg subset than in the FOXP3 low-expressing non-T reg and rT reg subsets from both patients with SLE and HCs (Supplemental Fig. 5E and F) . These data show that the level of FOXP3 expression serves as an indicator for the functional state of the T reg population not only in HCs but also in patients with SLE. Consequently, the loss of FOXP3 high-expressing aT reg , characterized by the highest CD25 and the lowest CD127 expression levels, would lead to a deficit in suppressive T reg in SLE. When the percentage of both FOXP3 low-expressing (rT reg and non-T reg ) subsets among FOXP3 + CD4 + T cells was compared with those of HCs, it was significantly increased in patients with SLE, whereas the percentage of the aT reg subset was significantly decreased (Fig. 3E) . The percentage of the aT reg subset among FOXP3 + CD4 + T cells was also significantly decreased after in vitro treatment of purified CD4 T cells from healthy donors with IL-7 (Fig. 3F) . Therefore, IL-7 signaling appears to decrease the frequency of aT reg within the FOXP3 + pool of cells. When we examined the absolute aT reg counts in blood from patients with SLE and those with RA, they were significantly decreased in patients with SLE compared the DCs (Fig. 3G) .
Because perturbed homeostasis of T regs with the suppressive phenotype could be related to different responses to homeostatic cytokines, we compared the IL-2-and IL-7-induced pSTAT5 levels between FOXP3 + CD4 + T cell subsets from patients with SLE. Whole blood samples were stimulated by incubation with recombinant human IL-2 or IL-7 for 15 min, and intracellular pSTAT5 was evaluated in rT reg , non-T reg , and aT reg cells. We found that pSTAT5 MFI after IL-2 stimulation was significantly higher in aT reg than it was in rT reg and non-T reg subsets of CD4 T cells. (Fig. 3H) . In contrast, pSTAT5 MFI after IL-7 stimulation was significantly lower in FOXP3 high-expressing aT reg cells than it was in the 2 FOXP3 low-expressing subsets of CD4 T cells (Fig.  3I) . Therefore, the aT reg subset, which was decreased in the pool of FOXP3 + cells from patients with SLE, was also characterized by the lowest IL-7-induced pSTAT5 among FOXP3 + CD4 + T cells.
pSTAT5 and Bcl2 protein expression imbalance between T con and aT reg
To assess the homeostatic balance between activated-effector T regs [18, 33] and conventional CD4 T cells, STAT5 phosphorylation levels were compared in aT reg and FOXP3 2 T con subsets + T cells from patients with SLE, incubated with anti-IL-7 and anti-IL-2 Abs for 30 min as compared with basal, untreated samples (n = 11). r s , Spearman correlation coefficient; NS, not significant; **P = 0.001-0.01, ***P = 0.0001-0.001, ****P , 0.0001. (Fig. 4A) . In contrast to aT reg , T con displayed significantly higher pSTAT5 levels in patients with SLE than it did in HCs. pSTAT5 levels in FOXP3 2 T con from patients with SLE were also significantly higher than in aT reg (Fig. 4B) , consistent with their significantly higher IL-7Ra (CD127) expression (Fig. 4C) .
To further estimate the selectivity of IL-7 signaling for the 2 specific CD4 T cell subsets, pSTAT5 was analyzed in T con and aT reg in response to stimulation with different concentrations of recombinant human IL-7. Figure 4D compares the ratio of the pSTAT5 MFI between T con and aT reg after stimulation with IL-7 for a 4-log range of cytokine concentrations. After stimulation with the highest concentration (10 ng/ml) of IL-7 the T con -pSTAT5:aT reg -pSTAT5 ratio was not significantly different in patients with SLE than it was in HCs. However, at lower IL-7 concentrations (1-1000 pg/ml), which better compared to levels found in sera from patients with SLE (Fig. 2E ), higher levels of Stat5 activation in T con than in aT reg from patients with SLE resulted in the significantly higher T con -pSTAT5:aT reg -pSTAT5 MFI ratio in patients with SLE than in HCs. Such imbalanced T con :aT reg STAT5 phosphorylation after stimulation with low IL-7 concentrations suggested greater a responsiveness of SLE T con to IL-7 compared with that of aT reg .
The T con :aT reg pSTAT5 MFI ratio, calculated between unstimulated-basal pSTAT5 levels in T con and aT reg subsets, was also significantly higher in patients with SLE than in HCs (Fig. 4E) .
When we analyzed Bcl2 protein expression, significantly higher levels were found in T con than in aT reg cells from both patients with SLE and HCs. However, in contrast to T con , Bcl2 protein levels were not significantly increased in aT reg cells from patients with SLE compared with HCs (Fig. 4F) . Therefore, in addition to imbalanced basal STAT5 phosphorylation, a shift in the homeostatic balance between T con and aT reg toward increased T con Bcl2 expression was found in patients with SLE.
Relationship between pSTAT5 and Ki-67 expression in CD4 T cell subsets
To assess the relationship between turnover-homeostasis of CD4 T cell subsets and STAT5 phosphorylation, the expression /L) in blood from patients with SLE (n = 39) and DCs (n = 29). (H and I) pSTAT5 levels (MFI) after simulation with recombinant human IL-2 (100 ng/ml) and IL-7 (10 ng/ml) for 15 min in rT reg , aT reg , and non-T reg subsets of CD4 + T cells from patients with SLE (n = 6). NS, not significant; *P , 0.05, **P = 0.001-0.01,***P = 0.0001-0.001, ****P , 0.0001.
of Ki-67 was determined as an indicator of proliferation [36] in peripheral blood FOXP3 2 T con and aT reg subsets (Fig. 4G ). T con subsets were identified among gated CD4 + T cells as shown on a representative FOXP3 vs. CD45RA zebra plot from a patient with SLE. (B) pSTAT5 levels (MFI) in T con and aT reg subsets from patients with SLE (n = 34) and HCs (n = 33). (C) CD127 expression levels (MFI) on T con and aT reg subsets from patients with SLE (n = 22). (D) T con -pSTAT5:aT reg -pSTAT5 ratio from patients with SLE (closed circles, n = 6) and HCs (open squares, n = 6) in response to recombinant human IL-7 challenge: means and SD for a given IL-7 concentration are shown. (E) Ratio of basal T con -pSTAT5 MFI to basal aT reg -pSTAT5 MFI (T con -pSTAT5:aT reg -pSTAT5) from patients with SLE (n = 34) and HCs (n = 33) (F) Bcl2 protein expression (MFI) in T con and aT reg from patients with SLE (n = 22) and HCs (n = 21). (G) Representative histogram shows Ki-67 expression in T con and aT reg from a patient with SLE. (H and I) Percentage of Ki-67 + cells (%Ki-67 + ) among T con and aT reg and the ratio of aT reg %Ki-67 + to T con % Ki-67 + (aT reg -%Ki-67 + :T con -%Ki-67 + ) from patients with SLE (n = 30), HCs (n = 18), and DCs (n = 22) (J) Purified CD4 + T cells from HCs (n = 6) were cultured for 3 d in the presence or absence of recombinant human IL-7 (0.1 ng/ml). Bar graph shows the aT reg -%Ki-67 + :T con -%Ki-67 + ratio for treated (IL-7) and untreated (2) samples. (K) Correlation between pSTAT5 (MFI) in CD4 T cells and percentage of Ki-67 + cells among T cons (left) and aT regs (right) from patients with SLE (n = 30). r s , Spearman correlation coefficient; *P , 0.05, **P = 0.001-0.01, ****P , 0.0001.
Ki-67
+ cells among aT regs was significantly less in patients with SLE as well as in patients with RA compared with the HCs (Fig.  4H) . The percentage of Ki-67 + cells among aT regs was not significantly different in patients with SLE and in DCs. However, the ratio of the percentage of + cells between aT regs and T cons was significantly increased in patients with SLE compared with both HCs and DCs (Fig. 4I) .
When we examined the ability of IL-7 to influence Ki-67 expression in CD4 T cell subsets from healthy donors, the ratio of the percentage of Ki-67 + cells between aT reg and T con was significantly decreased after in vitro treatment with recombinant human IL-7 (Fig. 4J) . Therefore, IL-7 signaling appears to decrease the Ki-67 + cell ratio between aT regs and T cons . To determine whether basal STAT5 activation is involved in the turnover of T con and aT reg subsets from patients with SLE, we examined the relationship between the levels of T con /aT reg Ki-67 expression and pSTAT5. Consistent with the crucial role of IL-7 signaling in the proliferation of T con , CD4 T cell pSTAT5 MFI was significantly and positively correlated with the percentage of Ki-67 + T cons . In contrast, no significant correlation was found between the proliferation of the aT reg subset (the percentage of Ki-67 + cells among aT regs ) and CD4 T cell pSTAT5 MFI (Fig. 4K) .
Together, our results suggested that imbalanced IL-7-dependent STAT5 signaling, which was related to antiapoptotic Bcl2 protein and Ki-67 expression, may confer survival and proliferative advantage to T cons over aT regs from patients with SLE.
pSTAT5 imbalance between T cons and aT regs and the association with SLE disease course Basal pSTAT5 levels in T cons and aT regs were analyzed in blood samples from 39 patients with SLE and no moderate or severe disease activity (no BILAG score A or B in any system). pSTAT5 MFI was significantly increased in T cons , but not aT regs , from patients with SLE compared with patients with RA and HCs. In contrast, pSTAT5 levels were significantly increased in aT regs , but not T cons , from patients with RA compared with HCs (Fig. 5A) .
pSTAT5 imbalance between T cons and aT regs , as assessed by the ratio of pSTAT5 MFI between T cons and aT regs , was significantly greater in patients with SLE than it was in DCs. The T con -pSTAT5:aT reg -pSTAT5 ratio was significantly increased in patients with SLE, but not in patients with RA, compared with HCs (Fig. 5B) .
Finally, we investigated whether patients with pSTAT5 imbalances between T cons and aT regs (an increased T con -pSTAT5:aT reg -pSTAT5 ratio) at the start of follow-up would experience a more-aggressive disease course, using the approach described recently [25, 37] . The cutoff value for the increased T con -pSTAT5:aT reg -pSTAT5 ratio was determined as the means 6 2 SD (1.87) T con -pSTAT5:aT regpSTAT5 ratio in HCs. The SLE cohort composed of 39 patients with no moderate or severe disease activity at enrollment (no BILAG score A or B in any system) and with subgroups defined based on the T con -pSTAT5:aT reg -pSTAT5 ratio (Table 1 and 2) was followed for up to 1000 d. We found that 75% of patients with SLE in group 1 with T con -pSTAT5:aT reg -pSTAT5 ratio higher than 1.87 had disease flares within 500 d after enrollment, compared with only 9% of patients in group 2 with the lower T con -pSTAT5:aT reg -pSTAT5 ratio (Fig. 5C ). The patients in the former group had more flares per year of follow-up than did the patients with lower T con -pSTAT5:aT reg -pSTAT5 ratios: flare rate normalized to duration of follow-up at 500 d (mean flare rate of 0.82/y vs. 0.06/y; P , 0.0001) and at 1000 d (0.51/y vs. 0.08/y; P , 0.0001) (Fig. 5D) . No significant association with other clinical or laboratory parameters was seen (Table 1) , although patients with preexisting disease in group 1 had more immunosuppression before enrollment. In addition, mycophenolate mofetil and rituximab were used as induction therapy only in this group (Table 2 ). This suggests that it was not a relative lack of prior therapy that resulted in the increased flare frequency in group 1 with the increased T con -pSTAT5:aT regpSTAT5 ratios. When pSTAT5 status was examined during follow-up, time-adjusted cumulative CD4 T cell pSTAT5 levels (adjusted mean CD4 T cell pSTAT5 MFI) in sequential samples from the patients in the group 1 were significantly higher than those in the group 2 ( Fig. 5E and F) . Therefore, in patients with T con /aT reg signaling imbalances, CD4 T cell STAT5 activation was maintained at higher levels during follow-up. In addition, significant positive correlation was found between the adjusted mean CD4 T cell pSTAT5 MFI in sequential samples from the same patient and time-adjusted cumulative disease activity (adjusted mean SLEDAI) (Fig. 5G) .
DISCUSSION
Homeostatic imbalances between FOXP3
+ T reg and T con cells, associated with IL-2 deprivation, as well as excess IL-7, were shown to exacerbate autoimmune manifestations in murine models of SLE [38, 39] .
Results of our study demonstrated that patients with SLE who have more aggressive disease were characterized by greater activation of the STAT5 signaling pathway in T cons as compared with the aT reg subset. In addition to significantly decreased aT reg counts, the homeostatic balance between T cons and aT regs was disturbed in patients with SLE, with a shift toward T con proliferation, as assessed by Ki-67 expression, which was positively correlated with levels of pSTAT5 in CD4 T cells. Bcl2 expression and pSTAT5 levels were significantly increased in SLE T cons , but not the aT reg subset, consistent with the differences in their responses to homeostatic cytokine IL-7.
Increases in Bcl2 protein expression and a reduction in cell death rates after in vitro treatment with homeostatic cytokines, which were even more pronounced in T cells from patients with SLE, have been described previously [4, 5] . T cell Bcl2 protein content, which is dependent on STAT5 function [12] , was significantly increased in our patients with SLE and was significantly correlated to constitutive phosphorylation of STAT5, localized to nucleus. This suggested functional homeostatic cytokine signaling on the level of pSTAT5, nuclear translocation, and associated Bcl2 protein expression in T cells from patients with SLE.
Homeostatic cytokine signaling and constitutive pSTAT5 has previously been described in diseases associated with CD4 T cell lymphopenia [20, 40] . HIV infection, however, was shown to perturb IL-7 signaling by impairing the access of pSTAT5 to the nuclear compartment [41] . The use of multispectral imaging cytometry allowed us to demonstrate pSTAT5 nuclear localization in T cells from patients with SLE immediately ex vivo. In a recent study, increased T cell pSTAT5 levels in isolated PBMC from patients with SLE were described, but signaling was not investigated in T cell subsets [42] . The CD4 + subset of T cells from our patients with SLE displayed significantly increased pSTAT5 levels. In addition, the significant, negative correlation between CD4 counts and serum IL-7 levels suggested increased IL-7 availability, which has previously been associated with CD4 T cell depletion in other diseases [7, 8] .
In patients with SLE, increased serum sIL7Ra has been reported [43] , which was previously shown to potentiate IL-7 bioactivity and to promote autoimmunity [44] . Although CD4 counts were not significantly lower in our patients with SLE, their IL-7 levels were significantly higher than those of HCs, which could suggest diminished consumption of IL-7 and a secondary increase in IL-7 availability, previously described in the presence of sIL7Ra [44] .
SOCS1 up-regulation was also shown to be diminished in the presence of sIL7Ra compared with IL-7 alone [44] . SOCS1 inhibits STAT5 phosphorylation responses to homeostatic cytokines, and deletion of SOCS1 in T cells increases their sensitivity to IL-7 [45] . The lack of significant correlation between serum IL-7 levels and abnormal activation of STAT5 signaling downstream of the IL-7R in CD4 T cells from our patients with SLE may, therefore, be related to differences in patients' levels of sIL-7Ra and signaling inhibitors, such as SOCS1.
Significantly decreased pSTAT5 after incubation with anti-IL-7, but not with anti-IL-2 Abs, and the highest pSTAT5 levels in the subset of SLE CD4 T cells with the highest IL-7Ra (CD127) expression, suggested a dominant effect of IL-7 on basal STAT5 phosphorylation.
Priming with homeostatic cytokines IL-7 and IL-15 was shown before to amplify p-ERK in human T cells after TCR stimulation [13] . Consistent with that, significantly higher ERK phosphorylation responses after anti-CD3 stimulation were found in the population of SLE CD4 T cells characterized by high pSTAT5-a signature of in vivo exposure to homeostatic cytokine.
Previously, in vitro studies of IL-7 signaling in healthy donors showed that FOXP3 + T regs characterized by low expression of the IL-7Ra [31] can sense IL-7 at a concentration 10-1000-fold higher than conventional T cell subsets [46, 47] . Conversely, a recent study described distinct differences in the ERK pathway, even between FOXP3 + subsets [48] .
Consistent with the differences in CD127 expression found between FOXP3 + subsets, pSTAT5 levels were significantly lower in aT regs than non-T reg and rT reg subsets from our patients with SLE.
Results of recent studies in mice identified IL-7 as a necessary factor to sustain expression of high levels of CD25 at the T reg surface in vivo, thereby supporting the functional activity of effector T regs by increasing their IL-2 sensitivity [49, 50] .
We found significantly increased pSTAT5 levels, even in the CD25 2 subset of SLE FOXP3 + cells, but not in FOXP3 highexpressing aT regs , which were characterized by the highest levels of CD25 expression. Decreased frequency of T regs with the highest CD25 and FOXP3 expression levels has previously been linked to a deficit in T reg functionality in SLE [51, 52] .
The greatest expression of the CD39 molecule in an aT reg subset was consistent with the results of previous studies, which have shown enrichment of suppressive cells in the aT reg compartment not only in HCs but also in patients with SLE [18, 53] . In contrast to an intact, suppressive function of the aT reg , an impaired suppressive function of rT regs was previously demonstrated in patients with SLE [53] . IL-7 was shown to abrogate the capacity of T regs to suppress proliferation of T con cells in response to TCR activators, including alloantigens and autoantigens [47] . Of note, suppressor activity was affected at lower IL-7 concentrations in naïve rT regs than it was in the CD45RA 2 T reg subset [47] .
As shown by phenotypic comparison of the aT reg , non-T reg , and rT reg subsets and their responses to stimulation with IL-7, the decrease of the aT reg subset in the pool of FOXP3 + cells from our patients with SLE may be driven by IL-7 signaling and could lead to a relatively reduced availability of activated-effector T regs [18, 33] that are capable of efficiently counteracting pathogenic T cons .
In addition to the imbalance in basal pSTAT5 between T cons and aT regs , we also found increased responsiveness of SLE T cons to IL-7 compared with that of aT regs , as shown by an increased T con :aT reg pSTAT5 ratio after stimulation with low IL-7 concentrations.
IL-7 maintains T cell survival by regulating anti-and proapoptotic members of the Bcl2 family [9] , but recent studies have suggested that not all T cell populations are equally dependent on IL-7 signaling. Increased IL-7 was shown to contribute to an expansion and activation of human autoreactive T cells via a direct effect on cells that express the IL-7Ra at greater levels [6] . Comparison of Bcl2 expression and proliferation between T con and aT reg subsets indicated that T cons , but not activated-effector T regs [18, 33] , were the preferential responders to augmented homeostatic STAT5 signaling found in our patients with SLE.
Previously, it was determined that the aT reg subset is characterized by high susceptibility to apoptosis and enriched by Ki-67-expressing cells [18] . Although the percentage of Ki-67 + aT regs was decreased in patients with RA, the significantly decreased aT reg :T con proliferation ratio was specific for patients with SLE and could be reproduced between aT regs and T cons from healthy donors after IL-7 treatment in vitro.
IL-7-dependent sensitization of the TCR signaling pathway, which enabled human T cell responses to RA self-antigens, was previously associated with increased proliferative responses [13] . Significant correlation between pSTAT5 and increased Ki-67 expression in T cons from our patients provides evidence for a possible mechanism by which homeostatic cytokine signaling, in addition to lowering the TCR threshold that must be surpassed by the (auto) antigen, perturbs T con /aT reg homeostasis in SLE by driving greater T con proliferation.
McKinney et al. [25] have shown, using transcriptional profiling in isolated CD8 + T cells, that genes of the IL7R pathway identify a distinct patient subgroup with worse long-term prognosis in different autoimmune diseases, including SLE [37] .
An increased T con -pSTAT5:aT reg -pSTAT5 ratio was found in our patients with SLE and was, despite even more-intensive, prior immunosuppressive therapy in the high pSTAT5 ratio patient group 1, associated with relapsing disease during follow-up. Therefore, such STAT5 signaling aberrations, which reflect specifically altered responses of patients in T con /T reg subsets to homeostatic cytokines, could also serve as a useful biomarker of SLE disease severity.
Time-adjusted cumulative CD4 T cell pSTAT5 levels during the long-term follow-up were significantly higher in patients with increased T con :aT reg pSTAT5 ratios and were significantly correlated to adjusted mean SLEDAI, which is also used as the surrogate marker of disease severity [26, 27] .
It was recently demonstrated that severe, chronic graftversus-host disease is characterized by a decreased T reg :T con pSTAT5 ratio [20] . Daily administration of low-dose IL-2, which induces selective expansion of functional T regs and clinical improvement [54] , can lead to rapid correction of such STAT5 signaling imbalances between T regs and T cons with selective increases of STAT5 phosphorylation in T regs [20] . Consequently, IL-2 therapy induced a series of changes in T reg homeostasis, including their increased turnover in Ki-67 expression, increased Bcl2 expression, and enhanced resistance to apoptosis [20] . In a recent study, a low-dose IL-2 regimen increased T reg Ki-67 expression and T reg levels of CD25 expression in all 5 treated patients with SLE [52] .
In lupus-prone mice, excess IL-7 was shown to support proliferation of autoreactive T cells and progression of autoimmunity. Moreover, the IL-7Ra blockade reduced T cell activation and autoimmune manifestations, even when applied at advanced disease stages [39] .
Imbalanced homeostatic STAT5 signaling, which was associated with not only Bcl2 and Ki-67 expression but also relapsing disease during follow-up, could support expansion of pathogenic T cons over suppressive-activated T regs and may, thereby, predispose patients with SLE to more-severe disease courses.
T cell homeostatic proliferation, which was also found in humans to be associated with autoimmunity [55] , was shown to be IL-7 dependent and to drive expansion of pathogenic T con subsets [6] .
Correction of the IL-7-dependent T con /aT reg STAT5 signaling imbalances found in our patients could, by selectively affecting survival/proliferation of pathogenic-conventional CD4 T cells, restore homeostasis between T cons and suppressive-effector T regs and may represent a promising therapeutic approach in SLE.
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